| 15-102-14 | A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine | Open |
| A011401 | Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
| Open |
| A011502-CIRB | A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial | Open |
| A171601-CIRB | A Phase II Trial Assessing The Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer | Open |
| AFT-25 | Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: a Phase III Prospective Randomized Trial | Open |
| AFT-25-REX | Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: a Phase III Prospective Randomized Trial | Open |
| ALTERNATE/A011106 | ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study | Not Open |
| APEC1621SC | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) | Open |
| FADOI03-2016 | Apixaban for the Treatment of Venous Thromboembolism in Patients with Cancer: a Prospective Randomized Open Blinded End-Point (PROBE) Study - The Caravaggio Study | Open |
| G1T48-01 | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Open |
| H3B-6545-A001-101 | A Phase I-II multicenter, open label trial of H3B-6545, a covalent antagonist of estrogen receptor alpha, in women with locally advanced or metastatic estrogen receptor-positive, HER2 negative breast cancer | Open |
| LCCC1622 | A Single Arm Evaluation of False Negative Rate of Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases | Open |
| LCCC1829 | HARMONY: Harnessing the Analysis of RNA expression and Molecular subtype to Optimize Novel TherapY for Metastatic Breast Cancer | Open |
| LCCC1853 | Novel MRI sequence- MR Fingerprinting in Breast MRI- Feasibility study | Open |
| MK-3475-355-REX | A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer – (KEYNOTE-355) | Open (affiliates only) |
| ML28897PRO/02 | My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents. | Open |
| NC-6300-001 | A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma | Open |
| NCI10020-CIRB | A Phase II Open-Label, Randomized Study of PARP Inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer | Open |
| NRG-BR003-CIRB | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High- Risk Node-Negative Triple-Negative Invasive Breast Cancer | Open |
| NRG-BR003-CIRB-REX | NRG-BR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer | Open |
| NSABP-B-54-I-REX | Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy | Open (affiliates only) |
| NSABP-B-59/GBG-96 | A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo | Open (affiliates only) |
| ONT-380-206 | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) | Open |
| OSU-16106 | Multi-Institution Phase II Trial of Intraoperative Electron Beam Radiotherapy Boost at the Time of Breast Conserving Surgery with Oncoplastic Reconstruction in Women with Early-Stage Breast Cancer | Open |
| RTOG-1119 | RTOG-1119: Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of RTOG and KROG | Open |
| S1207-CIRB | Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer | Open (affiliates only) |
| S1418-CIRB | Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy | Open |
| TBCRC-037 | A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer | Open |
| TBCRC-042 | A Randomized Phase 2 Window-of-Opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions. | Not Open |
| TBCRC-043 | TBCRC 043: A Phase II trial of Atezolizumab (anti-PDL1) with Carboplatin in Patients with Metastatic Triple Negative Breast Cancer | Open |